Becton Dickinson and Company (BDX) : The consensus price target for Becton Dickinson and Company (BDX) is $185 for the short term with a standard deviation of $9.29. The most optimist securities analyst among the 12 who monitor the stock believes that the stock can reach $200, however, the pessimist price target for the company is $169.
Becton Dickinson and Company (BDX) : 13 analysts are covering Becton Dickinson and Company (BDX) and their average rating on the stock is 1.62, which is read as a Buy. 9 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 4 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Also, In the latest statement by the brokerage house, UBS maintains its outlook on Becton Dickinson and Company (NYSE:BDX). The current rating of the shares is Buy, according to the research report released by the firm. The brokerage firm raises the price target from $182 per share to $195 per share. The rating by the firm was issued on August 5, 2016.
Becton Dickinson and Company (NYSE:BDX): The stock opened at $177.71 on Thursday but the bulls could not build on the opening and the stock topped out at $177.78 for the day. The stock traded down to $175.71 during the day, due to lack of any buying support eventually closed down at $177.02 with a loss of -0.11% for the day. The stock had closed at $177.21 on the previous day. The total traded volume was 609,017 shares.
Becton, Dickinson and Company is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories, pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Companys Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Companys BD Medical segment focuses on providing solutions to reduce the spread of infection, enhance diabetes treatment and advance drug delivery. The Companys BD Diagnostics provides products for the safe collection and transport of diagnostics specimens, as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers, clinical researchers, laboratory professionals and clinicians.